Literature DB >> 26846777

Osteoporosis across chronic liver disease.

M Guarino1, I Loperto1, S Camera1, V Cossiga1, C Di Somma2, A Colao2, N Caporaso1, F Morisco3.   

Abstract

Osteoporosis is a complication of chronic liver disease, with impact on morbidity, quality of life, and survival. The progress of medicine and the new therapies stretched the disease's natural history and improved the survival of patients with liver disease. So, it is fundamental to make better the quality of life and to prevent complications. Metabolic bone disorders are common complications of chronic liver disease (CLD). Patients with CLD have an increased risk of bone fractures, with significant impact on morbidity, quality of life, and even on survival. Bone diseases, including osteomalacia, osteoporosis, and osteopenia, are frequently observed in many types of liver disease. The pathogenesis of damage and the mechanisms of bone loss are different in relation to the specific liver disease. The relevance of these conditions induced many authors to create a new nosographic entity known as "hepatic osteodystrophy", although this term is rarely used anymore and it is now commonly referred to as osteopenia or osteoporosis associated with chronic liver disease. This review is based on the personal experiences of the authors and upon research done of the available literature on this subject matter. The authors searched the PubMed database for publications containing the term "liver disease" in combination with "bone disease", "hepatic osteodistrophy", "osteoporosis", "osteopenia", "osteomalacia", and "fractures". They selected publications from the past 10 years but did not exclude older seminal publications, especially for colestatic liver diseases. This review of literature shows that osteoporosis crosses all CLD. It is important to underline that the progress of medicine and the new therapies stretched the disease's natural history and improved the survival of patients with CLD. It is fundamental to make better the quality of life and it is mandatory to prevent complications and in particular the osteoporotic ones, especially fractures.

Entities:  

Keywords:  Fractures; Liver disease; Osteoporosis

Mesh:

Year:  2016        PMID: 26846777     DOI: 10.1007/s00198-016-3512-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  93 in total

1.  Hormone replacement therapy in women with liver disease.

Authors:  J O'Donohue; R Williams
Journal:  Br J Obstet Gynaecol       Date:  1997-01

Review 2.  Hepatic osteodystrophy.

Authors:  Angelo Gatta; Alberto Verardo; Marco Di Pascoli; Sandro Giannini; Massimo Bolognesi
Journal:  Clin Cases Miner Bone Metab       Date:  2014-09

Review 3.  [Assessment of the treatment of glucocorticoid-induced osteoporosis].

Authors:  Shogo Asano; Atsushi Suzuki
Journal:  Clin Calcium       Date:  2013-03

4.  Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis.

Authors:  Núria Guañabens; Albert Parés; Inmaculada Ros; Llorenç Caballería; Francesca Pons; Sergi Vidal; Ana Monegal; Pilar Peris; Juan Rodés
Journal:  J Hepatol       Date:  2005-01-13       Impact factor: 25.083

5.  Association between bone mineral density and metabolic syndrome in pre- and postmenopausal women.

Authors:  Yun Kyung Jeon; Jeong Gyu Lee; Sang Soo Kim; Bo Hyun Kim; Seong-Jang Kim; Yong Ki Kim; In Joo Kim
Journal:  Endocr J       Date:  2011       Impact factor: 2.349

Review 6.  Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment.

Authors:  Albert Parés; Núria Guañabens
Journal:  Clin Liver Dis       Date:  2008-05       Impact factor: 6.126

7.  Decreased bone mineral density in men with metabolic syndrome alone and with type 2 diabetes.

Authors:  Subhashini Yaturu; Stacey Humphrey; Christopher Landry; Sushil K Jain
Journal:  Med Sci Monit       Date:  2009-01

Review 8.  Osteoimmunology--the hidden immune regulation of bone.

Authors:  J Caetano-Lopes; H Canhão; J E Fonseca
Journal:  Autoimmun Rev       Date:  2008-08-21       Impact factor: 9.754

9.  The impact of fragility fractures on health-related quality of life in patients with primary sclerosing cholangitis.

Authors:  Joanna Raszeja-Wyszomirska; Robert Kucharski; Marta Zygmunt; Krzysztof Safranow; Tomasz Miazgowski
Journal:  Hepat Mon       Date:  2015-04-25       Impact factor: 0.660

10.  Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis.

Authors:  Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ana Patrícia Paula; Cristiano Zerbini; Diogo S Domiciano; Helenice Gonçalves; Jaime S Danowski; João F Marques Neto; Laura M C Mendonça; Mailze C Bezerra; Maria Teresa Terreri; Marta Imamura; Pedro Weingrill; Perola G Plapler; Sebastião Radominski; Tatiana Tourinho; Vera L Szejnfeld; Nathalia C Andrada
Journal:  Rev Bras Reumatol       Date:  2012-08
View more
  11 in total

Review 1.  Current Controversies: Are Free Vitamin Metabolite Levels a More Accurate Assessment of Vitamin D Status than Total Levels?

Authors:  Daniel D Bikle; Sofie Malmstroem; Janice Schwartz
Journal:  Endocrinol Metab Clin North Am       Date:  2017-12       Impact factor: 4.741

2.  The relationship between fatty liver index and bone mineral density in Koreans: KNHANES 2010-2011.

Authors:  S H Ahn; D H Seo; S H Kim; M-S Nam; S Hong
Journal:  Osteoporos Int       Date:  2017-10-19       Impact factor: 4.507

3.  The epidemiology of wrist fractures in older men: the Osteoporotic Fractures in Men (MrOS) study.

Authors:  N C Wright; E R Hooker; C M Nielson; K E Ensrud; S L Harrison; E S Orwoll; E Barrett-Connor
Journal:  Osteoporos Int       Date:  2018-01-17       Impact factor: 4.507

Review 4.  Vitamin D metabolites in captivity? Should we measure free or total 25(OH)D to assess vitamin D status?

Authors:  Daniel Bikle; Roger Bouillon; Ravi Thadhani; Inez Schoenmakers
Journal:  J Steroid Biochem Mol Biol       Date:  2017-01-16       Impact factor: 4.292

5.  Bone microarchitecture and bone turnover in hepatic cirrhosis.

Authors:  R Wakolbinger; C Muschitz; G Scheriau; G Bodlaj; R Kocijan; X Feichtinger; J E Schanda; J Haschka; H Resch; P Pietschmann
Journal:  Osteoporos Int       Date:  2019-02-20       Impact factor: 4.507

Review 6.  Hepatocrinology.

Authors:  Sanjay Kalra; Saptarshi Bhattacharya; Pawan Rawal
Journal:  Med Sci (Basel)       Date:  2021-06-01

7.  Risk factors for osteoporosis in liver cirrhosis patients measured by transient elastography.

Authors:  Jian-Ping Zheng; Hai-Xiong Miao; Shao-Wei Zheng; Wei-le Liu; Chu-Qun Chen; Hao-Bo Zhong; Sheng-Fa Li; Yong-Ping Fang; Chun-Han Sun
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

8.  miRNAs in bone tissue correlate to bone mineral density and circulating miRNAs are gender independent in osteoporotic patients.

Authors:  Sarah Kelch; Elizabeth R Balmayor; Claudine Seeliger; Helen Vester; Jan S Kirschke; Martijn van Griensven
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

9.  Suboptimal Level of Bone-Forming Cells in Advanced Cirrhosis are Associated with Hepatic Osteodystrophy.

Authors:  Chhagan Bihari; Deepika Lal; Monika Thakur; Sukriti Sukriti; Dhananjay Mathur; Anupama G Patil; Lovkesh Anand; Guresh Kumar; Shvetank Sharma; Shalini Thapar; Apurba Rajbongshi; Archana Rastogi; Anupam Kumar; Shiv K Sarin
Journal:  Hepatol Commun       Date:  2018-09-04

10.  Risk factors associated with hepatic osteopathy in HBV related cirrhosis measured by liver stiffness: An Observational study.

Authors:  Wei Zhang; Hui Gong; Zengcun Su; Xuping Zhang; Shujuan Cao
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.